Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zinc, cancer study

This article was originally published in The Tan Sheet

Executive Summary

Stage III and IV head and neck cancer patients receiving zinc supplementation have a better three-year, local-free survival rate than matched control patients, according to researchers of the Chi-Mei Foundation Medical Center in Taiwan. In a double-blinded, randomized, placebo-controlled study beginning in 2003 and published in the International Journal of Radiation Oncology Biology Physics, 50 patients undergoing radiotherapy for two months took 75 mg per day of zinc supplement Pro-Z, a powder extracted from bovine prostate that is chelated to zinc. Patients in the experimental and control groups had similar results; patients with any of the four cancer stages had marginally better three-year LFS rates when supplemented with zinc, though insignificant. However, patients with stage III and IV cancer had notably better and significant LFS rates when taking Pro-Z and undergoing radiotherapy...

You may also be interested in...



Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel